rasilez
novartis new zealand ltd - aliskiren hemifumarate 331.5mg equivalent to 300 mg aliskiren; ; - film coated tablet - 300 mg - active: aliskiren hemifumarate 331.5mg equivalent to 300 mg aliskiren excipient: colloidal silicon dioxide crospovidone basic coating premix white basic coating premix red basic coating premix black magnesium stearate microcrystalline cellulose povidone - rasilez is indicated for the treatment of hypertension.
rasilez hct tablets film-coated
novartis farma s.p.a. - aliskiren (aliskiren hemifumarate), hydrochlorothiazide - tablets film-coated - 150mg+ 25mg
rasilez hct tablets film-coated
novartis farma s.p.a. - aliskiren (aliskiren hemifumarate), hydrochlorothiazide - tablets film-coated - 300mg+ 25mg
rasilez hct tablets film-coated
novartis farma s.p.a. - aliskiren (aliskiren hemifumarate), hydrochlorothiazide - tablets film-coated - 300mg+ 12,5mg
rasilez hct tablets film-coated
novartis farma s.p.a. - aliskiren (aliskiren hemifumarate), hydrochlorothiazide - tablets film-coated - 150mg+ 12,5mg
rasilez 150 mg
novartis pharma services ag - aliskiren 150 mg - film coated tablets - aliskiren - treatment of essential hypertension.
rasilez 300 mg
novartis pharma services ag - aliskiren 300 mg - film coated tablets - aliskiren - treatment of essential hypertension.
rasilez film coated tablet 150 mg
yousif mahmood hussain & bahrain pharmacy co - aliskiren hemifumarate - film coated tablet - 150
rasilez film coated tablet 300 mg
yousif mahmood hussain & bahrain pharmacy co - aliskiren hemifumarate - film coated tablet - 300
rasilez hct film coated tablet 150 /12.5mg
yousif mahmood hussain & bahrain pharmacy co - aliskiren hemifumarate, hydrochlorothiazide - film coated tablet - 150